United States
Germany
Japan
United Kingdom
China
EPS8 (NM_004447) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC205300L1V
- LentiORF®
-
Lenti ORF particles, EPS8 (Myc-DDK tagged) - Human epidermal growth factor receptor pathway substrate 8 (EPS8), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 8,930.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
| Product Data | |
| Product Name | EPS8 (NM_004447) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | DFNB102 |
| Vector | pLenti-C-Myc-DDK |
| ACCN | NM_004447 |
| ORF Size | 2466 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC205300).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_004447.4 |
| RefSeq Size | 4088 bp |
| RefSeq ORF | 2469 bp |
| Locus ID | 2059 |
| Domains | SH3, PID |
| Protein Families | Druggable Genome |
| MW | 91.9 kDa |
| Gene Summary | This gene encodes a member of the EPS8 family. This protein contains one PH domain and one SH3 domain. It functions as part of the EGFR pathway, though its exact role has not been determined. Highly similar proteins in other organisms are involved in the transduction of signals from Ras to Rac and growth factor-mediated actin remodeling. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
Customer
Reviews
Loading...
